HER-2 testing and trastuzurnab therapy for metastatic breast cancer: A cost-effectiveness analysis

被引:179
作者
Elkin, EB
Weinstein, KC
Winer, EP
Kuntz, KM
Schnitt, SJ
Weeks, JC
机构
[1] Harvard Univ, Ctr Risk Anal, Cambridge, MA 02138 USA
[2] Sch Publ Hlth, Cambridge, England
[3] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[4] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
关键词
D O I
10.1200/JCO.2004.04.158
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Trastuzumab therapy has been shown to benefit metastatic breast cancer patients whose tumors exhibit HER-2 protein overexpression or gene amplification. Several tests of varying accuracy and cost are available to identify candidates for trastuzumab. We estimated the cost-effectiveness of alternative HER-2 testing and trastuzumab treatment strategies. Patients and Methods We performed a decision analysis using a state-transition model to simulate clinical practice in a hypothetical cohort of 65-year-old metastatic breast cancer patients. Outcomes were quality-adjusted life-years (QALYs), lifetime cost, and incremental cost-effectiveness ratio (ICER). Interventions included testing with the HercepTest (DAKO, Carpinteria, CA) immunolhistochemical assay alone, fluorescence in situ hybridization (FISH) alone, and both tests, followed by trastuzumab and chemotherapy for patients with positive test results and chemotherapy alone for patients with negative test results. Results In the base case, initial HercepTest with FISH confirmation of all positive results had an ICER of $125,000 per QALY gained. The incremental cost-effectiveness of initial FISH was $145,000 per QALY gained. Other strategies yielded the same or poorer effectiveness at a higher cost, or lower effectiveness at a lower cost, but with a less favorable ICER. These findings persisted under a range of assumptions, and only changes in test characteristics substantially altered results. Conclusion It is more cost-effective to use FISH alone or as confirmation of all positive HercepTest results, rather than using FISH to confirm only weakly positive results or using HercepTest alone. When multiple tests are available to identify treatment candidates, test characteristics may have a substantial impact on the aggregate costs and effectiveness of treatment. (C) 2004 by American Society of Clinical Oncology.
引用
收藏
页码:854 / 863
页数:10
相关论文
共 93 条
[1]  
*AM SOC CLIN ONC, 2001, REF MD PAYM METH CAN
[2]  
[Anonymous], 1998, BRISTOL MYERS SQUIBB
[3]  
[Anonymous], 2001, Proc Am Soc Oncol
[4]   Evaluating HER2 amplification and overexpression in breast cancer [J].
Bartlett, JMS ;
Going, JJ ;
Mallon, EA ;
Watters, AD ;
Reeves, JR ;
Stanton, P ;
Richmond, J ;
Donald, B ;
Ferrier, R ;
Cooke, TG .
JOURNAL OF PATHOLOGY, 2001, 195 (04) :422-428
[5]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[6]   Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression [J].
Bhargava, R ;
Naeem, R ;
Marconi, S ;
Luszcz, J ;
Garb, J ;
Gasparini, R ;
Otis, CN .
HUMAN PATHOLOGY, 2001, 32 (12) :1344-1350
[7]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[8]  
Birner P, 2001, CLIN CANCER RES, V7, P1669
[9]   HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer [J].
Bozzetti, C ;
Nizzoli, R ;
Guazzi, A ;
Flora, M ;
Bassano, C ;
Crafa, P ;
Naldi, N ;
Cascinu, S .
ANNALS OF ONCOLOGY, 2002, 13 (09) :1398-1403
[10]   Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients [J].
Brown, RE ;
Hutton, J .
ANTI-CANCER DRUGS, 1998, 9 (10) :899-907